Neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of COVID-19
vaccines and have received emergency use authorization as therapeutics. However, viral …

The SARS-CoV-2 spike (S) glycoprotein contains an immunodominant receptor-binding
domain (RBD) targeted by most neutralizing antibodies (Abs) in COVID-19 patient plasma. Little …

Antibodies are a principal determinant of immunity for most RNA viruses and have promise
to reduce infection or disease during major epidemics. The novel coronavirus SARS-CoV-2 …

The global emergence of many severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
variants jeopardizes the protective antiviral immunity induced after infection or …

Antibody-based interventions against SARS-CoV-2 could limit morbidity, mortality, and
possibly transmission. An anticipated correlate of such countermeasures is the level of …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cell entry starts with membrane
attachment and ends with spike (S) protein–catalyzed membrane fusion depending on …

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused millions of
human infections, and an effective vaccine is critical to mitigate coronavirus-induced disease …

Although neutralizing antibodies against the SARS-CoV-2 spike (S) protein are a goal of
most COVID-19 vaccines and being developed as therapeutics, escape mutations could …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is associated
with a hyperinflammatory state and lymphocytopenia, a hallmark that appears as both …

IFITMs are broad antiviral factors that block incoming virions in endosomal vesicles, protecting
target cells from infection. In the case of HIV-1, we and others reported the existence of an …